Viatris Slashes Full-Year Revenue Guidance By $800m

Strengthening US Dollar Continues To Be Significant Headwind

 
• By Dean Rudge
  
Arrows down (Zoonar GmbH/Alamy Stock Photo)
Viatris is looking to launch lenalidomide in 2022 • Source: Shutterstock (Zoonar GmbH / Alamy Stock Photo/Alamy Stock Photo)

More from Earnings

More from Business